Oxyntomodulin : a novel potential treatment for obesity.
The prevalence of obesity is increasing rapidly and the associated morbidity and mortality has led to an urgent need for potential therapeutic targets to reduce appetite and food intake. Gut hormones released after eating that coordinate digestive activity and promote satiety are novel potential treatments for obesity. Oxyntomodulin is a gut hormone that is produced by the L cells in the small intestine and reduces food intake. It is timely to review some of the original literature on oxyntomodulin, to evaluate what is already known about the peptide, and also to set the recent findings on its effects on food intake and bodyweight into context.Recent studies have shown that long-term peripheral administration of oxyntomodulin to rats leads to reduced food intake and reduced weight gain. Studies in humans have demonstrated that acute administration reduces food intake by 19%. When given preprandially by subcutaneous injection three times daily, oxyntomodulin resulted in a reduction in food intake and mean weight loss of 2.8kg over 4 weeks. Oxyntomodulin thus represents a potential therapy for obesity.The mechanism of action of oxyntomodulin is not known. Current evidence suggests that it acts via the glucagon-like peptide 1 (GLP-1) receptor. There may be an additional receptor in the gastric mucosa mediating its effects on gastric acid secretion. Although oxyntomodulin probably acts via the GLP-1 receptor, the two peptides differentially regulate food intake and energy expenditure in the mouse.Oxyntomodulin represents a potential therapy for obesity. Further work will help to clarify its mechanisms of action.
Druce
Maralyn R
MR
Department of Metabolic Medicine, Hammersmith Hospital, Imperial College London, London, UK.
Bloom
Stephen R
SR
D000818:Animals; D004435:Eating / Q000187:drug effects; D005768:Gastrointestinal Hormones / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology; D053767:Glucagon-Like Peptide 2 / Q000494:pharmacology; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D053772:Oxyntomodulin / Q000494:pharmacology
D005768:Gastrointestinal Hormones; D053767:Glucagon-Like Peptide 2; D053772:Oxyntomodulin; D052216:Glucagon-Like Peptide 1